When did Viridian Therapeutics, Inc. report Q4 2024 earnings?

Viridian Therapeutics, Inc. (VRDN) reported Q4 2024 earnings on February 27, 2025 before market open.

What were Viridian Therapeutics, Inc.'s Q4 2024 revenue and EPS?

Viridian Therapeutics, Inc. reported revenue of $72.0K and eps of $-0.81 for Q4 2024.

Did Viridian Therapeutics, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $50.0K by $22.0K. EPS beat the consensus estimate of $-1.05 by $0.24.

Where can I find Viridian Therapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001590750-25-000004) directly on SEC EDGAR. The filing index links above go to sec.gov.

Viridian Therapeutics, Inc. VRDN Q4 2024 Annual earnings

Reported February 27, 2025 · Before market open

Revenue$72.0KBeat by $22.0K

EPS-$0.81Beat by $0.24

Revenue estimate$50.0K

EPS estimate-$1.05

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$30.5K

EPS estimate-$1.02

Financials

Q4 2024

Income statement

See full

Revenue$72.0K0.0%

Operating income-$87.5M-22.4%

Net income-$79.7M-19.2%

Balance sheet

See full

Cash & equivalents$99.6M-3.1%

Total debt$2.5M-88.5%

Total equity$671.6M+51.9%

Total assets$742.4M+51.4%

Cash flow

See full

Operating cash flow-$73.3M-93.0%

CapEx$114.0K+138%

Free cash flow-$73.4M-93.0%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$1.52B+32.6%

Enterprise value$1.42B+33.5%

P/S5,028.2×+1,381×

Profitability

See full

Operating margin-99,018.5%+28,242pp

Net margin-89,387.1%+19,705pp

FCF margin-77,096%+34,325pp

Returns & leverage

See full

Return on equity-48.5%-6.2pp

Debt / equity0×0.0×

Current ratio15.4×-2.8×

Versus estimates

Revenue

Q1 2026$141.0KBeat by $104.9K Q4 2025$132.0KMiss by $18.2M Q3 2025$70.6MBeat by $54.8M Q2 2025$75.0K Q1 2025$72.0KBeat by $27.9K

Q4 2024$72.0KBeat by $22.0K

Diluted EPS

Q1 2026-$0.90Beat by $0.16 Q4 2025-$1.08Miss by $0.18 Q3 2025-$0.34Beat by $0.48 Q2 2025-$1.00In line Q1 2025-$0.87Beat by $0.08

Q4 2024-$0.81Beat by $0.24

Ask the moment Viridian Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Viridian Therapeutics, Inc. report Q4 2024 earnings?: Viridian Therapeutics, Inc. (VRDN) reported Q4 2024 earnings on February 27, 2025 before market open.
What were Viridian Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Viridian Therapeutics, Inc. reported revenue of $72.0K and eps of $-0.81 for Q4 2024.
Did Viridian Therapeutics, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $50.0K by $22.0K. EPS beat the consensus estimate of $-1.05 by $0.24.
Where can I find Viridian Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001590750-25-000004) directly on SEC EDGAR. The filing index links above go to sec.gov.